Connect with us
Open enrollment is underway as 193 counties lose every general Medicare Advantage drug plan, and a 63-day Medigap window is...
Medical groups posted 2026-27 flu, COVID-19 and RSV advice, but pharmacies, state boards and FDA labels still decide who can get vaccinated.
Rasonque lists at $39,800 a month after FDA approval, yet Medicare’s $2,100 Part D cap can close a patient’s share after one fill.
AB 2244 would put a state Non-Ultraprocessed Certified seal on grocery packages, tying supermarket labels to California’s school-food UPF rules before a.
Congo’s Bundibugyo Ebola outbreak has killed 3,007 people, and the only licensed shot now going into arms is still a Zaire vaccine WHO will not endorse...
Child mental health A&E visits in England rose 36% by 2025, fastest among six- to nine-year-olds still left outside new youth hubs.
Medicare's GLP-1 Bridge sells Wegovy and Zepbound for $50, then routes sleep apnea and diabetes patients back to Part D copays of hundreds of dollars.
The 2026 heart attack definition recodes SCAD and spasm as primary attacks and requires sex-specific troponin cutoffs.
Hospital lobbyists want Medicaid cuts rolled back, yet the rural fund caps hospital care pay at 15 percent before 2027 work rules hit.
AstraZeneca’s Wainua miss lets stabilizer drugs claim first-line ATTR-CM care as Alnylam defends Amvuttra’s trial design.
AstraZeneca’s Wainua missed its ATTR-CM endpoint, and the 1.14 combo ratio cements oral stabilizer pills as first-line care over gene silencers.
